Entrada Narrows Quarterly Loss To $39.7 Million And Extends Funding Horizon Into 2027

Lower research costs helped trim the loss as Entrada prepares for four expected clinical readouts through the first half of 2027.

Share
Entrada Narrows Quarterly Loss To $39.7 Million And Extends Funding Horizon Into 2027

Entrada Therapeutics, which develops investigational genetic medicines for muscle and inherited eye diseases, narrowed its third-quarter loss to $39.7 million from $44.1 million a year earlier, according to results accompanying its Thursday SEC filing. The company also extended its expected funding horizon into the fourth quarter of 2027, covering a period in which it expects four clinical data readouts.

Lower Spending, Less Cash

Entrada attributed the drop in research expenses to lower preclinical spending on Duchenne muscular dystrophy programs and reduced facility costs. Research expenses totaled $32.4 million, against $38.4 million in the third quarter of 2025; administrative expenses were $10.2 million, compared with $10.3 million, primarily because professional-services costs fell.

Collaboration revenue declined to $0.9 million from $1.6 million. The quarterly loss per share improved to $0.94 from $1.06, but the first nine months told a different story: net losses totaled $122.222 million, versus $104.586 million a year earlier, while collaboration revenue fell to $2.678 million from $24.122 million.

Cash, cash equivalents and marketable securities stood at $193.0 million on September 30, 2026, down from $295.7 million on December 31, 2025. Funding operations accounted primarily for that decline. Entrada's estimate that the money will last into the fourth quarter of 2027 rests on its current operating plans.

TRDA shares rose about 3% to $4.69 in Friday trading.

Duchenne Safety Results And Higher Doses

Duchenne is Entrada's main development focus. Its medicines combine a proprietary delivery peptide with short strands of nucleic acids intended to reach targets inside cells; its programs address patients whose mutations are suited to skipping particular sections of genetic instructions.

October results from the early-stage ENTR-601-45 trial met the study's main safety and tolerability goals, the company said. Participants received three doses of 5 milligrams per kilogram or placebo. Headache was the most common treatment-emergent adverse event; one participant experienced serious vomiting and fever events that resolved. Nobody discontinued, and the company reported no low-magnesium or kidney-safety concerns.

Those participants have moved into an open-label portion, where all receive the medicine, for six doses at the same level. Enrollment is complete and dosing continues in the 10-milligram-per-kilogram group, with results expected in the first half of 2027. A proposed group receiving up to 15 milligrams per kilogram depends on an independent safety committee's review. The FDA granted ENTR-601-45 orphan drug designation for Duchenne in October.

For ENTR-601-44, initial-dose participants have completed open-label dosing and entered a long-term extension. Entrada expects those longer-term results by year-end 2026, followed by results from the 12-milligram-per-kilogram group in the first quarter of 2027. Enrollment at 18 milligrams per kilogram is underway after an independent committee recommended proceeding in October.

Four Readouts, Including Vertex's Program

Entrada Chief Executive Officer Dipal Doshi said, “we expect four clinical data readouts through the first half of 2027.” That count includes anticipated interim results in the second half of 2026 from Vertex Pharmaceuticals' early-stage VX-670 trial for myotonic dystrophy type 1. Vertex has completed enrollment and dosing in the multiple-dose portion, which examines safety, preliminary efficacy and muscle function.

Entrada is also reviewing data from its lead programs before submitting further regulatory applications for ENTR-601-50 and ENTR-601-51. For its planned adult Duchenne study, management favors the highest advisable starting dose in advanced disease and plans further FDA discussions after reviewing safety and drug-response data.

Beyond muscle diseases, Entrada has two inherited-retinal-disease programs, including ENTR-801 for Usher syndrome type 2A. It plans to nominate a second eye-disease clinical candidate by year-end 2026.

The next expected ENTR-601-44 readout will examine longer-term safety and additional functional measures, including whether the early functional improvements persist.

Sources

More on Entrada Therapeutics

All Entrada Therapeutics (TRDA) coverage →